Rice-derived glucosylceramides up-regulate HLA-DR expression on myeloid dendritic cells to activate innate immune responses in healthy Japanese subjects: A randomized, placebo-controlled, double-blind trial
DOI:
https://doi.org/10.31989/ffhd.v15i8.1666Abstract
Introduction: In a prior study, we found that rice-derived glucosylceramides (GlCer) improved overall health and alleviated common cold symptoms, including nasal congestion, sore throat, coughing, headache, muscle pain, and diarrhea. One of the underlying mechanisms may involve the enhanced activation of antigen-presenting cells (APC) through Mincle, a c-type lectin receptor, and toll-like receptors. However, the clinical impact of GlCer on cell-mediated innate immunity, especially concerning APC, is not yet fully understood.
Objective: Therefore, we performed a clinical study on the effects of commercially available rice-GlCer (Oryza Ceramide®) on blood dendritic cells (DC).
Methods: The study was planned as a randomized, placebo-controlled, double-blind trial. Oryza Ceramide®-PCD (OC-PCD, 20 mg) tablets, each containing 0.6 mg of GlCer, were used as the active tablet. Twenty-two healthy Japanese individuals were enrolled and randomly divided to an active group (n=11) or placebo group (n=11 For 8 weeks, participants took three active tablets (60 mg of OC-PCD) or three placebo tablets daily. DC ratios and CD expression on DC during the intervention were set as the primary outcomes.
Results: All subjects finished the trial, and the per protocol set constituted 11 in each group. The myeloid DC (mDC) ratio and CD86 expression were significantly lower in the active group than in the placebo group. In contrast, HLA-DR expression on mDC was slightly higher in the active group. A stratified analysis of subjects with mean fluorescence intensity (MFI) for HLA-DR <60,000 revealed a significant high value in HLA-DR expression in the active group. A correlation was observed between changes in MFI values for HLA-DR and CD86 on mDC. However, plasmacytoid DC parameters did not change.
Novelty of the Study: Rice-derived GlCer was firstly clarified to enhance innate immune response specifically mDC to improve common cold symptoms through this clinical trial.
Conclusions: The oral administration of GlCer affected mDC by up-regulating the expression of HLA-DR and down-regulating CD86, which contribute to antigen presentation to T lymphocytes. The present results suggests that GlCer attenuate cold symptoms by enhancing the interaction between mDC and T lymphocytes.
Trial Registration: UMIN-CTR: UMIN000055299
Keywords: rice; glucosylceramide; HLA-DR; dendritic cells; CD86
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Functional Foods in Health and Disease - Online ISSN: 2160-3855; Print ISSN: 2378-7007
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.